Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Mallinckrodt
Dow
Colorcon
Medtronic

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,752,193

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,752,193
Title:Gene and mutations thereof associated with seizure and movement disorders
Abstract: The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype. Furthermore, the present invention provides kit for diagnosing or prognosing a seizure and/or movement disorder in a subject, or for identifying a subject with an increased likelihood of having an offspring predisposed to a seizure and/or movement disorder, wherein the kit includes one or more components for testing for the presence of an alteration in the PRRT2 gene in the subject.
Inventor(s): Heron; Sarah Elizabeth (Highbury, AU), Dibbens; Leanne Michelle (College Park, AU), Berkovic; Samuel Frank (Melbourne, AU), Scheffer; Ingrid Eileen (Melbourne, AU), Mulley; John Charles (Firle, AU)
Assignee: The University of Melbourne (Victoria, AU) Central Adelaide Local Health Network Incorporated (Adelaide, AU) Itek Ventures Pty Ltd (University of South Australia) (Salisbury South, AU)
Application Number:14/354,461
Patent Claims:1. A method for detecting a variant PRRT2 gene in a biological sample from a human subject, the method comprising: a) contacting a variant PRRT2 gene in a biological sample from a human subject with a detectably labeled oligonucleotide that specifically hybridizes to an alteration in a variant proline rich transmembrane protein 2 (PRRT2) nucleic acid but does not bind to a wild-type PRRT2 nucleic acid not comprising the alteration; and b) detecting hybridization of the oligonucleotide to the variant PRRT2 nucleic acid; wherein detecting hybridization indicates the presence of a variant PRRT2 gene in the sample; wherein said alteration in a variant PRRT2 nucleic acid is selected from the group consisting of: c.629-630insC, c.649-650insC, IVS2+1 G>T, IVS2+5G>A, and c.950G>A.

2. The method according to claim 1, wherein the alteration in the PRRT2 nucleic acid is c.629-630insC or c.649-650insC, which are both frameshift mutations in exon 2 of the PRRT2 gene.

3. The method according to claim 2, wherein the alteration is c.649-650insC, which is the result of an insertion of a cytosine (C) nucleotide residue after the nucleotide residue at a position corresponding to position 649 of SEQ ID NO: 9.

4. The method according to claim 1, wherein the alteration in the PRRT2 nucleic acid is IVS2+1 G>T or IVS2+5G>A, which are both splice site mutations in intron 2 of the PRRT2 gene.

5. The method according to claim 4, wherein the alteration is IVS2+1 G>T, which is the result of a guanine (G) to thymine (T) nucleotide substitution at a position corresponding to position +1 of intron 2 of the PRRT2 gene.

6. The method according to claim 1, wherein the alteration is c.950G>A, which is the result of a guanine (G) to adenine (A) nucleotide substitution at a position corresponding to position 950 of SEQ ID NO: 9.

7. The method according to claim 1, wherein the detectably labeled oligonucleotide is labelled with a fluorescent moiety.

8. The method according to claim 1, wherein the detectably labeled oligonucleotide is at least 20 nucleotides in length.

9. The method according to claim 4, wherein the alteration is IVS2+5G>A, which is the result of a guanine (G) to adenine (A) nucleotide substitution at a position corresponding to position +5 of intron 2 of the PRRT2 gene.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2011904493Oct 28, 2011
Australia2012900190Jan 18, 2012
PCT Information
PCT FiledOctober 29, 2012PCT Application Number:PCT/AU2012/001321
PCT Publication Date:May 02, 2013PCT Publication Number:WO2013/059884

Details for Patent 9,752,193

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The University of Melbourne (Victoria, AU) Central Adelaide Local Health Network Incorporated (Adelaide, AU) Itek Ventures Pty Ltd (University of South Australia) (Salisbury South, AU) 2031-10-28 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The University of Melbourne (Victoria, AU) Central Adelaide Local Health Network Incorporated (Adelaide, AU) Itek Ventures Pty Ltd (University of South Australia) (Salisbury South, AU) 2031-10-28 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The University of Melbourne (Victoria, AU) Central Adelaide Local Health Network Incorporated (Adelaide, AU) Itek Ventures Pty Ltd (University of South Australia) (Salisbury South, AU) 2031-10-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
AstraZeneca
Merck
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.